Pages that link to "Q38998427"

The following pages link to The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells (Q38998427):

Displaying 39 items.

• BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1 (Q34048020) (← links)
• Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. (Q38683494) (← links)
• Immune checkpoint dysfunction in large and medium vessel vasculitis (Q38897019) (← links)
• The sexist behaviour of immune checkpoint inhibitors in cancer therapy? (Q47138418) (← links)
• Blockade of PD-1 effectively inhibits in vivo malignant transformation of oral mucosa (Q47199775) (← links)
• Trial watch: Immune checkpoint blockers for cancer therapy (Q47393365) (← links)
• Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells (Q48096452) (← links)
• B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity. (Q50545382) (← links)
• SETD1B Activates iNOS Expression in Myeloid-Derived Suppressor Cells (Q51069953) (← links)
• Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy. (Q52606149) (← links)
• Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer. (Q55174561) (← links)
• Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer (Q56891212) (← links)
• Defining and Understanding Adaptive Resistance in Cancer Immunotherapy (Q57173769) (← links)
• Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy (Q57472982) (← links)
• Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression (Q58561592) (← links)
• Human Monocytic Suppressive Cells Promote Replication of and Alter Stability of Generated Granulomas (Q58572675) (← links)
• An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion (Q58610784) (← links)
• Chimeric tumor modeling reveals role of partial PDL1 expression in resistance to virally induced immunotherapy (Q61447759) (← links)
• Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy (Q64066131) (← links)
• Myeloid-Derived Suppressor Cells: Ductile Targets in Disease (Q64067969) (← links)
• Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment (Q64113924) (← links)
• Immunosenescence: the potential role of myeloid-derived suppressor cells (MDSC) in age-related immune deficiency (Q64234120) (← links)
• Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy. (Q64886488) (← links)
• Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes. (Q64943960) (← links)
• Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy. (Q64967509) (← links)
• IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells (Q88645659) (← links)
• The potential importance of myeloid-derived suppressor cells (MDSCs) in the pathogenesis of Alzheimer's disease (Q88738698) (← links)
• Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients (Q89457037) (← links)
• Unfolding innate mechanisms in the cancer microenvironment: The emerging role of the mesenchyme (Q89653483) (← links)
• Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer (Q89976160) (← links)
• Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease (Q90710469) (← links)
• ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment (Q91632394) (← links)
• AMPK activation inhibits the functions of myeloid-derived suppressor cells (MDSC): impact on cancer and aging (Q92299091) (← links)
• PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations (Q92477729) (← links)
• Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors (Q92511358) (← links)
• The Tumor Microenvironment in Colorectal Cancer Therapy (Q92642235) (← links)
• The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial (Q92862979) (← links)
• Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation (Q98465646) (← links)
• Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors (Q99565928) (← links)